Find stats on top websites
Industry Landscape
The healthcare data analytics industry is experiencing robust growth, driven by increasing demand for actionable insights from real-world data (RWD) to optimize drug development, commercial strategies, and patient outcomes. Advancements in AI/ML are enhancing data processing and analysis capabilities. Focus areas include oncology and rare diseases, with a strong emphasis on data integration and compliance.
Total Assets Under Management (AUM)
Healthcare Data Analytics Market Size in United States
~Approximately 14.5 billion USD
(19.0% CAGR)
Growth is fueled by: - Increasing adoption of EHRs and digital health technologies. - Rising need for data-driven decision-making in healthcare. - Expanding applications in personalized medicine and population health management.
Total Addressable Market
14.5 billion USD
Market Growth Stage
Pace of Market Growth
Emerging Technologies
Generative AI for Synthetic Data
Generative AI can create synthetic real-world data that mimics the statistical properties of actual patient data without compromising privacy, enabling broader data sharing and analysis.
Federated Learning
Federated learning allows AI models to be trained on decentralized datasets, such as those held by different hospitals or labs, without the data ever leaving its source, ensuring data privacy and security.
Explainable AI (XAI)
XAI focuses on developing AI models whose outputs and decisions can be understood and interpreted by humans, increasing trust and adoption in critical healthcare applications.
Impactful Policy Frameworks
Health Data and Technology: Transparency, Exchange, and Interoperability (HTI-1) Rule (2023)
The HTI-1 Rule, issued by the ONC in 2023, implements provisions of the 21st Century Cures Act, focusing on interoperability, information blocking, and health IT certification.
This rule increases the demand for interoperable data solutions, directly benefiting Prognos Health by fostering greater data exchange and integration opportunities.
FDA's Real-World Evidence (RWE) Program (Ongoing)
The FDA continues to expand its guidance and frameworks for the use of Real-World Evidence (RWE) from Real-World Data (RWD) to support regulatory decision-making, including approvals for new indications and post-market surveillance.
This policy validates and increases the market for Prognos Health's core offering, as pharmaceutical companies increasingly rely on RWD for drug development and regulatory submissions.
State-level Data Privacy Laws (e.g., California Privacy Rights Act - CPRA, 2023)
Beyond federal regulations like HIPAA, various US states (e.g., California, Virginia, Colorado) have enacted or updated comprehensive data privacy laws like CPRA, effective in 2023, granting consumers more control over their personal data.
These laws necessitate robust data anonymization, de-identification, and compliance measures for Prognos Health, ensuring their data practices align with evolving state-specific privacy mandates.
Transform Your Ideas into Action in Minutes with WaxWing
Sign up now and unleash the power of AI for your business growth
